Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (31-40 of 222) with videos related to

Pageof 23
Sort By:
Chinese Medical Journal Pulmonary and Critical Care Medicine|January 21, 2025
cGAS-STING signaling pathway in lung cancer: Regulation on antitumor immunity and application in immunotherapyJing Wu, Yingyao Chen, Mengqing Xie, et al.
Cancer Investigation|October 24, 2007
Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cellsChunxia Su, Bo Su, Liang Tang, et al.
Immunotargets and Therapy|September 11, 2024
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 BlockadeLi Wang, Li Liu, Jing Zhao, et al.
Frontiers in Pharmacology|September 16, 2022
Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitorsJianing Chen, Yaokai Wen, Xiangling Chu, et al.
Frontiers in Immunology|November 13, 2023
Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinomaQi Wang, Zhuoran Tang, Chunyu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2017
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challengeChunxia Su, Fei Zhou, Jiqiao Shen, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysisTao Jiang, Changyun Zhai, Chunxia Su, et al.
Translational Lung Cancer Research|May 19, 2020
An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case reportJuan Zhou, Fei Zhou, Huikang Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2017
The changing diagnostic pathway for lung cancer patients in Shanghai, ChinaTao Jiang, Shengxiang Ren, Xuefei Li, et al.
Clinical Lung Cancer|January 30, 2017
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall SurvivalTao Jiang, Meng Qiao, Fei Zhou, et al.
Pageof 23

Showing results (31-40 of 222) with videos related to

Sort By:
Pageof 23
Chinese Medical Journal Pulmonary and Critical Care Medicine|January 21, 2025
cGAS-STING signaling pathway in lung cancer: Regulation on antitumor immunity and application in immunotherapyJing Wu, Yingyao Chen, Mengqing Xie, et al.
Cancer Investigation|October 24, 2007
Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cellsChunxia Su, Bo Su, Liang Tang, et al.
Immunotargets and Therapy|September 11, 2024
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 BlockadeLi Wang, Li Liu, Jing Zhao, et al.
Frontiers in Pharmacology|September 16, 2022
Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitorsJianing Chen, Yaokai Wen, Xiangling Chu, et al.
Frontiers in Immunology|November 13, 2023
Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinomaQi Wang, Zhuoran Tang, Chunyu Li, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2017
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challengeChunxia Su, Fei Zhou, Jiqiao Shen, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysisTao Jiang, Changyun Zhai, Chunxia Su, et al.
Translational Lung Cancer Research|May 19, 2020
An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case reportJuan Zhou, Fei Zhou, Huikang Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2017
The changing diagnostic pathway for lung cancer patients in Shanghai, ChinaTao Jiang, Shengxiang Ren, Xuefei Li, et al.
Clinical Lung Cancer|January 30, 2017
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall SurvivalTao Jiang, Meng Qiao, Fei Zhou, et al.
Pageof 23